NASDAQ
9.11USD
-0.22 (-2.36%)
We have scored 4 news catalysts on DiaMedica Therapeutics Inc. (DMAC) over the past 12 months. The biggest single-day move next to one of them came Feb 7, 2026, when DMAC closed +8.0%: “DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages”. Coverage across the window leans positive (average ticker sentiment +0.63). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
486.9M
P/E
—
EPS
—
Beta
0.91
52W range
5.245-11
Day range
8.22–9.22
Open
9.02
Prev close
9.33
Volume
155.6K
Avg volume
188.4K
Dividend
0.00
IPO
2012-08-03
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about DiaMedica Therapeutics Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for DMAC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
